Cabozantinib in Treating Younger Patients With Recurrent or Refractory Solid Tumors

Official Title: A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors

This phase I trial studies the side effects and best dose of cabozantinib in treating younger patients with solid tumors that have come back or no longer respond to treatment. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Goldman, Stewart, MD

Contact Information:

Stewart Goldman, MD